Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older Than 65 Years

Introduction In multiple myeloma (MM) patients older than 65, the value of consolidation with autologous hematopoietic stem cell transplantation (auto-SCT) is not well defined. This is generally a population not represented in the pivotal clinical trials on which routine clinical practice is based. Even though the treatment of MM in older patients has improved in recent years, their survival is shortened, and most do not reach a second line. However, there are data supporting auto-SCT in this population with low associated mortality not related to relapse (NRM). TriNetX is a federated global health research platform that provides researchers with access to electronic medical records from healthcare organizations to conduct research studies. The aim of our study is to evaluate the safety and efficacy of auto-SCT in patients older than 65 years with MM with in a large population of world real life data. Methods We have analyzed the cohort of patients from our center (H12O) who have received an auto-SCT from January 2014 to March 2023. We defined two cohorts: Cohort 1, patients with > 65 years at the time of transplantation (n=59 patients) and Cohort 2, 65 years included n=6,876 patients; and Cohort 2, 65 y patients and 57 (28-65) in